SCHEMBL20134936

SCHEMBL20134936

CC(C)[C@]1(c2ccc(C(=O)N3CCC(c4nnc(-c5ccc(Cl)cc5)o4)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.42
PARP1 P09874 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 1/20 0.42
ALOX15B O15296 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.40
HDAC3 O15379 1/20 0.39
CYP2C9 P11712 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
MGLL Q99685 4/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
HTR2B P41595 1/20 0.37
HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134938 1.00 TNKS (0.42) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135447 0.93 TP53 (0.51) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135446 0.93 TP53 (0.51) TNKSPARP1PARP2TP53MAPT
SCHEMBL20134822 0.92 MAPT (0.46) TNKSPARP1PARP2TP53MAPT
SCHEMBL20134826 0.92 MAPT (0.46) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135252 0.92 TP53 (0.47) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135255 0.92 TP53 (0.47) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135477 0.86 TP53 (0.41) TNKSPARP1PARP2TP53MAPT
SCHEMBL20135474 0.86 TP53 (0.41) TNKSPARP1PARP2TP53MAPT
SCHEMBL20134784 0.85 TP53 (0.53) TNKSPARP1PARP2TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 TNKS 1975/4885PARP1 1254/4885PARP2 1184/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 TNKS 2369/4885PARP1 1682/4885PARP2 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.